SCHEMBL2265459

SCHEMBL2265459

Cc1cc(C#N)cc(C)c1Oc1ccnc(NC2CCN(c3cccc(S(C)(=O)=O)c3)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.41
CYP2C9 P11712 3/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
NR1H2 P55055 6/20 0.38
NR1H3 Q13133 6/20 0.38
GPR119 Q8TDV5 2/20 0.37
NPY5R Q15761 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
PSEN1 P49768 2/20 0.36
PSEN2 P49810 2/20 0.36
APH1B Q8WW43 2/20 0.36
NCSTN Q92542 2/20 0.36
APH1A Q96BI3 2/20 0.36
PSENEN Q9NZ42 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260009 0.95 KCNH2 (0.39) KCNH2CYP2C9CYP3A4CYP2C19NR1H2
SCHEMBL2260115 0.93 KCNH2 (0.47) KCNH2CYP2C9CYP3A4CYP2C19NR1H2
SCHEMBL2259038 0.89 KCNH2 (0.42) KCNH2CYP2C9NPY5RPSEN1PSEN2
SCHEMBL2260086 0.85 KCNH2 (0.51) KCNH2CYP2C9PSEN1PSEN2APH1B
SCHEMBL2260485 0.85 KCNH2 (0.52) KCNH2CYP2C9CYP3A4CYP2C19GPR119
SCHEMBL2259866 0.85 KCNH2 (0.47) KCNH2CYP2C9CYP3A4CYP2C19NR1H2
SCHEMBL2263677 0.85 KCNH2 (0.45) KCNH2CYP2C9NR1H2NR1H3GPR119
SCHEMBL2263668 0.85 KCNH2 (0.46) KCNH2CYP2C9CYP3A4CYP2C19NR1H2
SCHEMBL2264360 0.85 KCNH2 (0.40) KCNH2CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL2261155 0.83 KCNH2 (0.43) KCNH2CYP2C9NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP disclosed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US disclosed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A KCNH2 4033/4885CYP2C9 1382/4885CYP3A4 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.